Enovis (NYSE:ENOV) Director Purchases $24,984.00 in Stock

Enovis Corporation (NYSE:ENOV) Director Sharon Wienbar bought 900 shares of Enovis stock in a transaction dated Wednesday, November 11th. The stock was acquired at an average price of $27.76 per share, for a total transaction of $24,984.00. Following the completion of the acquisition, the director owned 45,551 shares in the company, valued at approximately $1,264,495.76. The trade was a 2.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Enovis Price Performance

Shares of NYSE ENOV traded up $0.10 during mid-day trading on Friday, hitting $27.74. 1,205,392 shares of the company’s stock traded hands, compared to its average volume of 1,879,055. The company’s 50-day moving average is $20.52 and its two-hundred day moving average is $23.22. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.15 and a quick ratio of 1.08. The company has a market capitalization of $1.60 billion, a P/E ratio of -3.01 and a beta of 1.31. Enovis Corporation has a 1 year low of $16.70 and a 1 year high of $31.67.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.11. The firm had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. Enovis had a negative net margin of 22.86% and a positive return on equity of 13.23%. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. On average, equities analysts anticipate that Enovis Corporation will post 3.15 EPS for the current fiscal year.

Key Enovis News

These are some of the ENOV news items that stood out recently:

• Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
• Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ENOV shares. UBS Group restated a “buy” rating and issued a $44.00 target price on shares of Enovis in a report on Monday, October 5th. BTIG Research upped their price target on shares of Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Weiss Ratings raised shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Canaccord Genuity Group decreased their price objective on shares of Enovis from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Finally, Needham & Company LLC boosted their target price on Enovis from $34.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average target price of $38.62.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IFP Advisors Inc lifted its position in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of Enovis during the second quarter valued at $36,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Enovis during the second quarter valued at $39,000. Public Employees Retirement System of Ohio bought a new position in shares of Enovis in the second quarter worth about $48,000. Finally, SBI Securities Co. Ltd. bought a new position in shares of Enovis in the third quarter worth about $55,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.